<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127631</url>
  </required_header>
  <id_info>
    <org_study_id>RADICALPC_009-001</org_study_id>
    <nct_id>NCT03127631</nct_id>
  </id_info>
  <brief_title>A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients</brief_title>
  <acronym>RADICALPC</acronym>
  <official_title>The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) &amp; A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cancer Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer.
      RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying
      cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RADICAL PC describes two prospective studies, one of which is embedded in the other. RADICAL
      PC1 is a prospective cohort study of men within one year of their first diagnosis of prostate
      cancer, or who are within one month of commencing Androgen Deprivation Therapy for the first
      time. Its goal will be to identify factors associated with the development of cardiovascular
      disease among men with prostate cancer, with a particular focus on Androgen Deprivation
      Therapy.RADICAL PC2 is a randomized, controlled trial embedded in RADICAL PC1. RADICAL PC2
      will test a systematic approach to modifying cardiovascular and lifestyle risk factors in men
      within one year of their first diagnosis of prostate cancer, or who are within one month of
      commencing Androgen Deprivation Therapy for the first time.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Outcome - Composite of Death, MI, Stroke, HF, or Arterial Revasc.</measure>
    <time_frame>3-5 years</time_frame>
    <description>The primary efficacy outcome is the occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure, or arterial revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Composite of Death, MI, Stroke or HF.</measure>
    <time_frame>3-5 years</time_frame>
    <description>The occurrence of the composite of all-cause mortality, myocardial infarction, stroke, or heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Composite of Death, MI, Stroke</measure>
    <time_frame>3-5 years</time_frame>
    <description>The composite of cardiovascular death, myocardial infarction, or stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Composite of Death, MI, Stroke, HF, A. Revasc, or Angina.</measure>
    <time_frame>3-5 years</time_frame>
    <description>The composite of cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, or unstable, new or worsening angina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Event Outcome - CV Death</measure>
    <time_frame>3-5 years</time_frame>
    <description>Cardiovascular death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Event Outcome - Myocardial Infarction</measure>
    <time_frame>3-5 years</time_frame>
    <description>Myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Event Outcome - Stroke</measure>
    <time_frame>3-5 years</time_frame>
    <description>Stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Event Outcome - Heart Failure</measure>
    <time_frame>3-5 years</time_frame>
    <description>Heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome - Event Outcome - Venous Thromboembolism</measure>
    <time_frame>3-5 years</time_frame>
    <description>Venous Thromboembolism.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Event Outcome - New or Worsening Angina</measure>
    <time_frame>3-5 years.</time_frame>
    <description>New or worsening angina.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Event Outcome - New Atrial Fibrillation</measure>
    <time_frame>3-5 years</time_frame>
    <description>New atrial fibrillation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Cognitive Function</measure>
    <time_frame>3-5 years</time_frame>
    <description>Cognitive function, as measured by the DSS test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Physical Measurement - Grip Strength</measure>
    <time_frame>3-5 years</time_frame>
    <description>Handgrip strength, as measured using the JAMAR Dynamometer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Physical Measurement - Timed Walk Test</measure>
    <time_frame>3-5 years</time_frame>
    <description>Timed-get-up-and-go-test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Physical Measurement - Walk Test</measure>
    <time_frame>3-5 years</time_frame>
    <description>Six-minute walk distance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Physical Measurement - Waist</measure>
    <time_frame>3-5 years</time_frame>
    <description>Waist circumference.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - HbA1c</measure>
    <time_frame>3-5 years</time_frame>
    <description>HbA1c concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Lipid Profile</measure>
    <time_frame>3-5 years</time_frame>
    <description>Lipid profile.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Event Outcome - Prostate Cancer Death</measure>
    <time_frame>3-5 years</time_frame>
    <description>Prostate cancer death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Prostate Cancer Characteristics - PC Progression</measure>
    <time_frame>3-5 years</time_frame>
    <description>Distant prostate cancer progression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Prostate Cancer Characteristics - Castrate-Resistant PC</measure>
    <time_frame>3-5 years</time_frame>
    <description>Development of castrate-resistant prostate cancer</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Prostate Cancer Characteristics - PSA Progression</measure>
    <time_frame>3-5 years</time_frame>
    <description>PSA progression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tertiary Efficacy Outcomes - Prostate Cancer Characteristics - Biochemical Failure</measure>
    <time_frame>3-5 years</time_frame>
    <description>Biochemical failure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcome - Emergent Adverse Event - Major Bleeding</measure>
    <time_frame>3-5 years</time_frame>
    <description>Major bleeding.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcome - Emergent Adverse Event - Myositis</measure>
    <time_frame>3-5 years</time_frame>
    <description>Myositis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcome - Emergent Adverse Event - Liver Injury</measure>
    <time_frame>3-5 years</time_frame>
    <description>Liver injury.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcome - Emergent Adverse Event - Kidney Injury</measure>
    <time_frame>3-5 years</time_frame>
    <description>Kidney injury.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Randomized - Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label antiplatelet agents, statins, ACE-I, and other antihypertensive medications where appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized - Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutrition</intervention_name>
    <description>Standardized advice on healthy diet practices.</description>
    <arm_group_label>Randomized - Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Standardized advice on exercise including strength training and resistance training exercises.</description>
    <arm_group_label>Randomized - Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking cessation</intervention_name>
    <description>Advice to quit smoking, if applicable, and on available aids to quit smoking,</description>
    <arm_group_label>Randomized - Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet agent, such as Aspirin, or other low-dose antiplatelet agent</intervention_name>
    <description>Prescription for a low-dose antiplatelet agent, such as aspirin 81-100mg daily or if intolerant of aspirin, other low-dose antiplatelet agent</description>
    <arm_group_label>Randomized - Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin, such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)</intervention_name>
    <description>Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.</description>
    <arm_group_label>Randomized - Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor</intervention_name>
    <description>Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater &gt;120mmHg, or other blood pressure lowering medication as applicable.</description>
    <arm_group_label>Randomized - Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. A man with a diagnosis of prostate cancer that is either:

          -  new (i.e. the diagnosis was made within 1 year of the baseline visit) or

          -  treated with Androgen Deprivation Therapy for the first time within 1 month prior to
             the baseline visit, or

          -  to be treated with Androgen Deprivation Therapy for the first time within 1 month
             after the baseline visit

        Exclusion Criteria:

          1. Unwilling to provide consent, or

          2. Are &lt;45 years of age

          3. Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if
             they:

               -  see a cardiologist every year, or

               -  are undertaking all of the following:

                    -  aspirin use, and

                    -  statin use, and

                    -  ACE-I use, and

                    -  exercise 4 or more times per week
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Darryl Leong, MBBs,MPH,PhD,FRACP,FESC</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayla Pohl, BA, CCRP</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40694</phone_ext>
    <email>kayla.pohl@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lori Blake</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40352</phone_ext>
    <email>lori.blake@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achal Sharma</last_name>
      <email>achal.sharma@williamoslerhs.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Tamara Wallington, MD,FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Karampatos</last_name>
      <email>karamps@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Bobby Shayegan, MD,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Thiessen</last_name>
      <email>thiessena@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Jehonathan Pinthus, MD,FRCS(C),PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Anstey, RN</last_name>
      <email>wendy.anstey@krcc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Robert Siemens, MD,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mounirah May</last_name>
      <email>mounirah.may@lhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Patrick Luke, MD,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Knee, ND, MSc</last_name>
      <email>cknee@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Luke Lavallee, MDCM,MSc,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Kebabdjian</last_name>
      <email>marlene.kebabdjian@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Laurence Klotz, MD,FRCS(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Matthys</last_name>
      <email>dominique.matthys.1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Emmanuelle Duceppe, MD,FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise St-Onge</last_name>
      <email>denise.st-onge@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Vincent Fradet, MD,PhD,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgen Deprivation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

